Strangvac, a vaccine against equine strangles, has been granted marketing authorisation in Norway

Stockholm, August 23, 2021 – Intervacc AB (“Intervacc”) announced today that the Norwegian Medicines Agency (NoMA) has granted a marketing authorisation for Strangvac® within Norway. Strangvac® is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally.

“We are very pleased that NoMA has granted a marketing authorization for Strangvac in Norway. The approval follows the positive opinion given by the European Medicines Agency, EMA, in June this year. This is an important step since we now can market the vaccine throughout the Nordic region as equine strangles does not respect borders and affects horses and the horse industry in our neighbouring countries and we feel great responsibility to spread the use of the vaccine to improve the health of horses.” says Andreas Andersson, CEO of Intervacc.

On August 16th this year, the European Commission approved Strangvac® for marketing in the EU and Norway is now the first country outside the European Union to approve the vaccine.

“Strangvac does not contain any live bacteria and is given to horses by intramuscular injection,” continued Emma Hartman, DVM and global product manager for the vaccine. “Vaccination generates an immune response against several different proteins from the bacteria Streptococcus equi, which causes strangles, but does not trigger any of the available diagnostic tests for strangles, so it can be used alongside current strategies as an important tool to reduce the impact of this devastating disease.”

“The approval of Strangvac for use in Norway is another breakthrough for this new generation of vaccines”, explains Dr Tim Wood, Head of CMC and Regulatory at Intervacc. “The proteins in Strangvac can simultaneously target several disease-causing mechanisms in a very selective manner. In the future, this technology has terrific potential to prevent many different diseases of animals.”

“Strangles is endemic in horse populations throughout the world and causes incalculable suffering, stress and economic cost to the equine industry” added Dr Andrew Waller, Chief Scientific Officer at Intervacc. “The development of Strangvac has been achieved in partnership with world-leading scientists at the Karolinska Institute and the Swedish University of Agricultural Sciences, SLU. We are excited about applying this ground-breaking science to prevent such an important disease of horses.”

For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com

This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 23, 2021.

About Intervacc
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company’s vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10